Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group

References

• Rodig SJ, Abramson JS, Pinkus GS, . Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174–7179.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Agostinelli C, Righi S, . Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007;92:566–567.
   PubMed Web of Science ®Google Scholar
• Salisbury JR, Rapson NT, Codd JD, . Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994;47:313–317.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005;5:39–51.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, . Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, . Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, . Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316–2323.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, . Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007;60:129–134.
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, . A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920–2924.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, . Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 2009;20:390–392.
   PubMed Web of Science ®Google Scholar
• Morris E, Thomson K, Craddock C, . Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865–3871.
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, . Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:10–15.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, . Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:7–9.
   PubMed Web of Science ®Google Scholar
• Lundin J, Porwit-MacDonald A, Rossmann ED, . Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004;18:484–490.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kennedy B, Moreton P, . Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004;103:2027–2031.
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, . Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3–12.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Cook G, Johnson PR, . Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res 2009;33:244–249.
   PubMed Web of Science ®Google Scholar
• Orlandi EM, Baldanti F, Citro A, . Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy. Haematologica 2008;93:1758–1760.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644–652.
   PubMed Web of Science ®Google Scholar
• Nobre CA, Callado MR, Lima JR, Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients. Rheumatol Int 2011 Aug 7. [Epub ahead of print]
   Google Scholar
• Kusumoto S, Tanaka Y, Mizokami M, . Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13–23.
   PubMed Web of Science ®Google Scholar
• Chae YS, Sohn SK, Kim JG, . Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol 2008;83:649–653.
   PubMed Web of Science ®Google Scholar
• Park SH, Choi SM, Lee DG, . Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis 2009;11:413–423.
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K, . Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 2008;87:310–318.
   PubMed Web of Science ®Google Scholar
• Kim H, Min YJ, Baek JH, . A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009;33:222–231.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Park Y, . Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs 2012;30:368–375.
   PubMed Web of Science ®Google Scholar
• Cavalli-Bjorkman N, Osby E, Lundin J, . Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol 2002;19:277–280.
   PubMed Web of Science ®Google Scholar
• Abruzzo LV, Rosales CM, Medeiros LJ, . Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630–636.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian HM, Thomas DA, . Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657–2663.
   PubMed Web of Science ®Google Scholar
• Elter T, Vehreschild JJ, Gribben J, . Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009;88:121–132.
   PubMed Web of Science ®Google Scholar
• Sandherr M, Einsele H, Hebart H, . Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:1051–1059.
   PubMed Web of Science ®Google Scholar
• Laurenti L, Piccioni P, Cattani P, . Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:1248–1252.
   PubMed Web of Science ®Google Scholar
• Gibbs SD, Herbert KE, McCormack C, . Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sezary syndrome. Eur J Haematol 2004;73:447–449.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Ho WM, . Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927–934.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, . Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254–258.
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001;34:204–206.
   PubMed Web of Science ®Google Scholar
• Brechot C, Thiers V, Kremsdorf D, . Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 2001;34:194–203.
   PubMed Web of Science ®Google Scholar
• Kim SM, Lee KS, Park CJ, . Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007;54:185–191.
   PubMed Web of Science ®Google Scholar
• Fabian I, Flidel O, Gadish M, . Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol 1993;21:1522–1527.
   PubMed Web of Science ®Google Scholar
• Au WY, Leung AY, Tse EW, . High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res 2008;32:547–551.
   PubMed Web of Science ®Google Scholar